PL2107069T3 - Nowe pochodne insuliny - Google Patents

Nowe pochodne insuliny

Info

Publication number
PL2107069T3
PL2107069T3 PL09165072T PL09165072T PL2107069T3 PL 2107069 T3 PL2107069 T3 PL 2107069T3 PL 09165072 T PL09165072 T PL 09165072T PL 09165072 T PL09165072 T PL 09165072T PL 2107069 T3 PL2107069 T3 PL 2107069T3
Authority
PL
Poland
Prior art keywords
insulin derivatives
novel insulin
novel
derivatives
insulin
Prior art date
Application number
PL09165072T
Other languages
English (en)
Inventor
Ib Jonassen
Thomas Hoeg-Jensen
Svend Havelund
Ulla Ribel-Madsen
Tagmose Tina Moller
Peter Madsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of PL2107069T3 publication Critical patent/PL2107069T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL09165072T 2003-08-05 2004-07-22 Nowe pochodne insuliny PL2107069T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200301129 2003-08-05
US49545103P 2003-08-14 2003-08-14
EP04739008A EP1660531A2 (en) 2003-08-05 2004-07-22 Novel insulin derivatives
EP09165072A EP2107069B1 (en) 2003-08-05 2004-07-22 Novel insulin derivatives

Publications (1)

Publication Number Publication Date
PL2107069T3 true PL2107069T3 (pl) 2013-06-28

Family

ID=34117520

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09165072T PL2107069T3 (pl) 2003-08-05 2004-07-22 Nowe pochodne insuliny

Country Status (18)

Country Link
US (3) US7615532B2 (pl)
EP (3) EP2264065B1 (pl)
JP (1) JP4463814B2 (pl)
KR (1) KR101159559B1 (pl)
AU (2) AU2004261353B2 (pl)
BE (2) BE2013C035I2 (pl)
BR (1) BRPI0413276B8 (pl)
CA (1) CA2531988C (pl)
CY (5) CY1113850T1 (pl)
FR (2) FR13C0035I2 (pl)
HU (1) HUS1300033I1 (pl)
IL (1) IL172980A (pl)
LU (2) LU92213I2 (pl)
MX (1) MXPA06001283A (pl)
NO (5) NO340925B1 (pl)
PL (1) PL2107069T3 (pl)
RU (1) RU2518460C2 (pl)
WO (1) WO2005012347A2 (pl)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012346A1 (en) * 2003-07-25 2005-02-10 Conjuchem, Inc. Long lasting insulin derivatives and methods thereof
MXPA06001283A (es) 2003-08-05 2006-04-11 Novo Nordisk As Derivados de insulina novedosos.
EP2256130B1 (en) * 2005-02-02 2013-09-25 Novo Nordisk A/S Novel insulin derivatives
EP2292653B1 (en) * 2005-02-02 2014-05-21 Novo Nordisk A/S Novel insulin derivatives
JP4808785B2 (ja) 2005-12-28 2011-11-02 ノボ・ノルデイスク・エー／エス インスリン組成物および組成物の製造方法
ATE482977T1 (de) * 2006-02-27 2010-10-15 Novo Nordisk As Insulinderivate
WO2007104736A2 (en) * 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
EP2015722B1 (en) 2006-04-28 2016-11-16 Avent, Inc. Antimicrobial site dressings
MX2008014061A (es) * 2006-05-09 2008-11-14 Novo Nordisk As Derivado de insulina.
CN101437849B (zh) * 2006-05-09 2015-09-30 诺沃-诺迪斯克有限公司 胰岛素衍生物
JP5269766B2 (ja) * 2006-05-09 2013-08-21 ノボ・ノルデイスク・エー／エス インスリン誘導体
JP5097900B2 (ja) * 2006-06-27 2012-12-12 独立行政法人物質・材料研究機構 有機酸又はこれらの誘導体の活性エステル体の製造方法
US20090306337A1 (en) * 2006-07-31 2009-12-10 Novo Nordisk A/S Pegylated, Extended Insulins
ES2601839T3 (es) 2006-09-22 2017-02-16 Novo Nordisk A/S Análogos de insulina resistentes a proteasas
ES2563038T3 (es) 2007-04-30 2016-03-10 Novo Nordisk A/S Método para secar una composición proteica, una composición proteica seca y una composición farmacéutica que comprende la proteína seca
EP2164466A1 (en) 2007-06-01 2010-03-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
CA2716159A1 (en) * 2007-06-01 2008-12-04 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
CN101677947B (zh) * 2007-06-13 2013-07-17 诺沃-诺迪斯克有限公司 包含胰岛素衍生物的药物制剂
MX2010001645A (es) * 2007-08-15 2010-03-10 Novo Nordisk As Analogos de insulina con una porcion de acil y alquilenglicol.
ES2526924T3 (es) 2007-08-15 2015-01-16 Novo Nordisk A/S Insulinas con una fracción acilo que comprende unidades repetitivas de aminoácidos que contienen alquilenglicol
CN101157725B (zh) * 2007-10-24 2012-07-25 中国药科大学 人胰岛素类似物的制备方法及用途
US8710000B2 (en) 2007-11-08 2014-04-29 Novo Nordisk A/S Insulin derivative
HUE030383T2 (en) 2007-11-16 2017-05-29 Novo Nordisk As Stable pharmaceutical formulations containing liraglutide and deglates
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
KR101755434B1 (ko) 2008-03-18 2017-07-10 노보 노르디스크 에이/에스 프로테아제 안정화되고, 아실화된 인슐린 유사체
ES2561208T3 (es) 2008-09-12 2016-02-25 Novo Nordisk A/S Método de acilación de un péptido o una proteína
KR20110085985A (ko) * 2008-10-30 2011-07-27 노보 노르디스크 에이/에스 하루 한번 주사 빈도보다 적은 인슐린 주사를 사용한 진성 당뇨병의 치료
AU2010207721B2 (en) 2009-01-23 2015-03-26 Novo Nordisk A/S FGF21 derivatives with albumin binder A-B-C-D-E- and their use
EP2493919A1 (en) 2009-10-30 2012-09-05 Novo Nordisk A/S Derivatives of cgrp
BR112012016853A2 (pt) * 2010-01-12 2017-10-17 Novo Nordisk As "composições farmacêuticas para administração oral de peptídeos de insulina".
JP5826772B2 (ja) 2010-02-16 2015-12-02 ノヴォ ノルディスク アー／エス コンジュゲートタンパク質
ES2582590T3 (es) 2010-02-16 2016-09-13 Novo Nordisk A/S Método de purificación
AU2011252127B2 (en) 2010-05-10 2014-02-20 Novo Nordisk A/S Process for the preparation of insulin-zinc complexes
EP2576593A4 (en) 2010-05-25 2014-07-09 Syngene Ltd PROCESS FOR THE SYNTHESIS OF DICARBA BRIDGES IN PEPTIDES
CN102933599A (zh) 2010-06-23 2013-02-13 诺沃—诺迪斯克有限公司 包含额外的二硫键的人胰岛素
CN104693302A (zh) * 2010-06-23 2015-06-10 诺沃—诺迪斯克有限公司 包含额外的二硫键的胰岛素衍生物
US8815798B2 (en) 2010-06-23 2014-08-26 Novo Nordisk A/S Insulin analogues containing additional disulfide bonds
US20140315797A1 (en) 2010-10-15 2014-10-23 Peter Madsen Novel N-Terminally Modified Insulin Derivatives
MX366314B (es) 2010-10-27 2019-07-05 Novo Nordisk As Uso de derivados de insulina por inyecciones con intervalos variables.
JP6049625B2 (ja) * 2010-10-27 2016-12-21 ノヴォ ノルディスク アー／エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
JP2013545782A (ja) 2010-12-14 2013-12-26 ノヴォ ノルディスク アー／エス 長時間作用型インスリンと組み合わせた速効型インスリン
WO2012110422A1 (en) 2011-02-15 2012-08-23 Novo Nordisk A/S Long-acting il-1 receptor antagonists
JP2014510739A (ja) * 2011-03-28 2014-05-01 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
WO2012140155A1 (en) 2011-04-14 2012-10-18 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
WO2012171994A1 (en) 2011-06-15 2012-12-20 Novo Nordisk A/S Multi substituted insulins
AR088161A1 (es) 2011-09-23 2014-05-14 Novo Nordisk As Analogos de glucagon
MX2014006698A (es) * 2011-12-15 2014-07-09 Shanghai Hengrui Pharm Co Ltd Analogo de insulina humana y derivado acilado del mismo.
WO2013093009A1 (en) 2011-12-21 2013-06-27 Novo Nordisk A/S N -terminally modified insulin derivatives
WO2013153000A2 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
US20160031962A1 (en) * 2012-04-20 2016-02-04 Kleomenis K. Barlos Solid phase peptide synthesis of insulin using side chain achored lysine
US9884094B2 (en) 2012-05-01 2018-02-06 Novo Nordisk A/S Method of treating diabetes mellitus
WO2014009316A1 (en) 2012-07-09 2014-01-16 Novo Nordisk A/S Novel use of insulin derivatives
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
CN104884078B (zh) 2012-10-17 2017-06-20 诺和诺德股份有限公司 用于口服肽递送的脂肪酸酰化d‑氨基酸
CA2895875A1 (en) 2012-12-21 2014-06-26 Sanofi Exendin-4 derivatives
EP2976096B1 (en) * 2013-03-20 2019-02-27 Novo Nordisk A/S Insulin dosing regimen
WO2014170496A1 (en) 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
SI3055325T1 (en) 2013-10-07 2018-05-31 Novo Nordisk A/S NEW DERIVATIVE ANALOGUE INSULINE
FR3013049B1 (fr) 2013-11-14 2015-11-13 You-Ping Chan Analogue de l'insuline glargine
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
MX2016010599A (es) 2014-02-18 2016-11-18 Novo Nordisk As Analogos de glucagon estables y uso para el tratamiento de hipoglucemia.
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
EP3151852A1 (en) 2014-06-04 2017-04-12 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
US20180244743A1 (en) 2015-08-25 2018-08-30 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
US20190010206A1 (en) 2015-08-25 2019-01-10 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
US10815287B2 (en) 2016-08-02 2020-10-27 Jiangsu Hengrui Medicine Co., Ltd. Acylated derivative of human insulin or analogue thereof
WO2018096164A1 (en) 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for treating diabetes
MA46890A (fr) 2016-11-28 2021-04-28 Novo Nordisk As Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme
US11278596B2 (en) 2016-11-28 2022-03-22 Novo Nordisk A/S Insulin degludec in cardiovascular conditions
MY194504A (en) 2016-12-16 2022-11-30 Novo Nordisk As Insulin containing pharmaceutical compositions
JOP20190273A1 (ar) * 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
WO2019154311A1 (zh) 2018-02-09 2019-08-15 江苏恒瑞医药股份有限公司 一种密码子优化的人胰岛素类似物前体基因和信号肽基因
CA3100869A1 (en) 2018-05-24 2019-11-28 Jiangsu Hengrui Medicine Co., Ltd. Method for preparing precursor of recombinant human insulin or analogue thereof
CN112313755B (zh) 2018-06-26 2024-05-28 诺和诺德股份有限公司 为基础胰岛素滴定提供剂量推荐的系统
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
KR102666154B1 (ko) 2018-08-08 2024-05-20 주식회사 대웅제약 지속형 인슐린 아날로그 및 그 복합체
KR20200080747A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법
KR20200080748A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법
WO2021009027A1 (en) 2019-07-12 2021-01-21 Novo Nordisk A/S High concentration insulin formulation
TW202434620A (zh) 2019-07-31 2024-09-01 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
AU2020418205A1 (en) 2019-12-30 2022-08-04 Gan & Lee Pharmaceuticals Co., Ltd. Insulin derivative
MX2022014309A (es) 2020-05-15 2022-12-07 Lilly Co Eli Compuestos de insulina acilada de accion temporal prolongada.
CN113773398B (zh) * 2020-06-10 2023-05-23 宁波鲲鹏生物科技有限公司 一种德谷胰岛素衍生物及其应用
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
US20250000948A1 (en) 2021-11-15 2025-01-02 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
WO2023143458A1 (zh) 2022-01-28 2023-08-03 甘李药业股份有限公司 酰化胰岛素
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
US20250154220A1 (en) * 2023-11-15 2025-05-15 Ambio, Inc. Insulin analogs for the treatment of human metabolic disorder and disease

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1212679B (de) 1957-08-03 1966-03-17 Novo Terapeutisk Labor As Verfahren zur Herstellung von Insulinloesungen
GB1042194A (en) 1962-04-30 1966-09-14 Olin Mathieson Insulin preparations
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3868358A (en) 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
GB1492997A (en) 1976-07-21 1977-11-23 Nat Res Dev Insulin derivatives
JPS5767548A (en) 1980-10-14 1982-04-24 Shionogi & Co Ltd Insulin analog and its preparation
FI78616C (fi) 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
DE3827533A1 (de) 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
WO1990007522A1 (en) 1988-12-23 1990-07-12 Novo Nordisk A/S Human insulin analogues
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
DK0506792T3 (da) 1989-12-21 1995-10-09 Novo Nordisk As Insulinpræparat, der indeholder nikotinsyre eller nikotinamid
DK45590D0 (pl) 1990-02-21 1990-02-21 Novo Nordisk As
JP3193398B2 (ja) 1991-07-23 2001-07-30 サンデン株式会社 ショ−ケ−ス
CA2125855C (en) 1991-12-20 2008-05-13 Hans Holmegaard Sorensen A stabilized pharmaceutical formulation comprising growth hormone and histidine
CA2171424C (en) * 1993-09-17 2002-06-04 Svend Havelund Acylated insulin
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
WO1996010417A1 (en) 1994-10-04 1996-04-11 Novo Nordisk A/S PREPARATIONS CONTAINING AspB28 HUMAN INSULIN AND NICOTINAMIDE
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5830999A (en) 1995-01-26 1998-11-03 Regents Of The University Of California Stabilization of insulin through ligand binding interations
CA2215694A1 (en) 1995-03-17 1996-09-26 Novo Nordisk A/S Insulin derivatives
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
EP2275119B1 (en) 1995-07-27 2013-09-25 Genentech, Inc. Stable isotonic lyophilized protein formulation
US6451970B1 (en) * 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
US5898267A (en) * 1996-04-10 1999-04-27 Mcdermott; Kevin Parabolic axial lighting device
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
AU3255297A (en) 1996-07-11 1998-02-09 Novo Nordisk A/S Selective acylation method
US5905140A (en) 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
ATE264871T1 (de) 1996-07-26 2004-05-15 Aventis Pharma Gmbh Insulinderivate mit erhöhter zinkbindung
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
AU6611998A (en) 1997-03-20 1998-10-20 Novo Nordisk A/S Therapeutic powder formulation for pulmonary administration, containing crystalline insulin
DE69806582T2 (de) 1997-03-20 2003-02-13 Novo Nordisk A/S, Bagsvaerd Verfahren zur herstellung eines therapeutischen puders durch copräzipitation von insulin und einem absorptionsverstärker
ES2260832T3 (es) * 1997-03-20 2006-11-01 Novo Nordisk A/S Cristales de insulina desprovistos de zinc utilizados en composiciones pulmonares.
US7097845B2 (en) 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
EP1283051B1 (en) 1997-06-13 2006-06-14 Eli Lilly And Company Stable insulin formulations
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
PT1025125E (pt) * 1997-10-24 2003-11-28 Novo Nordisk As Derivativos agregados da insulina humana
US20020155994A1 (en) 1997-10-24 2002-10-24 Svend Havelund Aggregates of human insulin derivatives
TR200001050T2 (tr) 1997-10-24 2000-08-21 Eli Lilly And Company Çözünmez insülin bileşimleri
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
CO4970787A1 (es) 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
AU1870099A (en) 1998-01-09 1999-07-26 Novo Nordisk A/S Stabilised insulin compositions
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
DE69920767T2 (de) 1998-10-16 2006-02-02 Novo Nordisk A/S Stabile konzentrierte Insulin Präparationen zur pulmonaren Verabreichung
EP1154796B1 (en) 1999-02-22 2007-06-20 University of Connecticut Novel albumin-free factor viii formulations
WO2000064940A1 (en) 1999-04-27 2000-11-02 Eli Lilly And Company Insulin crystals for pulmonary administration
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
ATE382057T1 (de) 2001-06-28 2008-01-15 Novo Nordisk As Stabile formulierung von modifiziertem glp-1
SK2432004A3 (sk) 2001-12-20 2005-04-01 Eli Lilly And Company Inzulínová zlúčenina s protrahovaným účinkom
AU2003208316A1 (en) 2002-03-13 2003-09-22 Novo Nordisk A/S Minimising body weight gain in insulin treatment
DE60335797D1 (de) 2002-05-07 2011-03-03 Novo Nordisk As Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
US20050232899A1 (en) 2002-05-31 2005-10-20 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US20040002451A1 (en) 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
KR100615389B1 (ko) 2002-08-23 2006-08-25 (주)헬릭서 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품
NZ562480A (en) 2002-10-29 2009-08-28 Alza Corp Stabilized, solid-state polypeptide particles
US20040138099A1 (en) 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
RU2358738C2 (ru) 2003-02-07 2009-06-20 Адзиномото Ко., Инк. Лекарственные средства для лечения сахарного диабета
EP1597367B1 (en) 2003-02-19 2010-07-07 Novartis AG Glycoprotein antigen sima135 expressed in metastatic human tumor cells
TW200529869A (en) 2003-03-04 2005-09-16 Technology Dev Company Ltd Delivery system for drug and cell therapy
EP1641487B1 (en) 2003-06-25 2012-02-29 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
US20050054818A1 (en) 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
EP2264066A3 (en) 2003-08-05 2011-07-27 Novo Nordisk A/S Novel insulin derivatives
MXPA06001283A (es) * 2003-08-05 2006-04-11 Novo Nordisk As Derivados de insulina novedosos.
MXPA06001698A (es) 2003-08-14 2006-05-19 Novo Nordisk Healthcare Ag Composicion farmaceutica liquida y acuosa de polipetidos de factor vii.
EP1663295A2 (en) 2003-09-01 2006-06-07 Novo Nordisk A/S Stable formulations of peptides
ES2229931B1 (es) 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
EP1687428A1 (en) 2003-11-14 2006-08-09 Novo Nordisk A/S Processes for making acylated insulin
BRPI0418115A (pt) 2003-12-23 2007-04-17 Pharmacia Corp formulação lìquida estável de hormÈnio de crescimento
DK1740154T3 (da) 2004-03-12 2009-08-31 Biodel Inc Insulinsammensætninger med forbedret absorption
EP1750750B1 (en) 2004-06-01 2012-02-01 Ares Trading S.A. Method of stabilizing proteins
US7632491B2 (en) 2004-08-12 2009-12-15 Schering Corporation Stable pegylated interferon formulation
EP1778723B1 (en) 2004-08-17 2012-11-14 Regeneron Pharmaceuticals, Inc. Il-1 antagonist formulations
WO2006051103A2 (en) 2004-11-12 2006-05-18 Novo Nordisk A/S Stable formulations of peptides
EP1817049B1 (en) 2004-11-22 2012-08-01 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
AU2006206272A1 (en) 2005-01-21 2006-07-27 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stabitity containing at least one counterion
EP2256130B1 (en) * 2005-02-02 2013-09-25 Novo Nordisk A/S Novel insulin derivatives
JP4808785B2 (ja) 2005-12-28 2011-11-02 ノボ・ノルデイスク・エー／エス インスリン組成物および組成物の製造方法
ATE482977T1 (de) 2006-02-27 2010-10-15 Novo Nordisk As Insulinderivate
JP2009533471A (ja) 2006-04-12 2009-09-17 バイオデル， インコーポレイテッド 即効型および長時間作用型組合せインスリン製剤
MX2008014061A (es) 2006-05-09 2008-11-14 Novo Nordisk As Derivado de insulina.
CN101677947B (zh) 2007-06-13 2013-07-17 诺沃-诺迪斯克有限公司 包含胰岛素衍生物的药物制剂
HUE030383T2 (en) 2007-11-16 2017-05-29 Novo Nordisk As Stable pharmaceutical formulations containing liraglutide and deglates
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物

Also Published As

Publication number Publication date
WO2005012347A2 (en) 2005-02-10
CY2013029PI1 (el) 2015-11-04
US20060183668A1 (en) 2006-08-17
CY2013027PI1 (el) 2015-11-04
AU2004261353A1 (en) 2005-02-10
CY2013029PI2 (el) 2015-11-04
US20100009899A1 (en) 2010-01-14
FR13C0035I1 (pl) 2013-08-09
BRPI0413276B1 (pt) 2020-03-03
CA2531988C (en) 2016-06-28
EP2107069A3 (en) 2009-11-25
NO2024004I1 (no) 2024-01-16
RU2518460C2 (ru) 2014-06-10
NO2018002I2 (no) 2018-08-20
NO340925B1 (no) 2017-07-17
AU2010200497A1 (en) 2010-03-04
LU92226I9 (pl) 2018-11-19
LU92213I2 (fr) 2013-08-23
MXPA06001283A (es) 2006-04-11
US7615532B2 (en) 2009-11-10
BE2013C038I2 (pl) 2023-12-14
IL172980A (en) 2013-10-31
BE2013C035I2 (pl) 2023-12-14
EP2107069A2 (en) 2009-10-07
EP1660531A2 (en) 2006-05-31
WO2005012347A3 (en) 2005-04-14
FR13C0035I2 (fr) 2014-03-07
LU92226I2 (fr) 2015-04-29
JP4463814B2 (ja) 2010-05-19
LU92213I9 (pl) 2018-11-19
CY2013027I1 (el) 2024-09-20
EP2264065A3 (en) 2011-07-27
CY2013029I2 (el) 2024-09-20
AU2004261353B2 (en) 2009-12-10
EP2264065B1 (en) 2017-03-08
CA2531988A1 (en) 2005-02-10
NO2018002I1 (no) 2018-01-11
CY2013027I2 (el) 2024-09-20
BRPI0413276A (pt) 2006-10-10
CY2013029I1 (pl) 2024-09-20
US8828923B2 (en) 2014-09-09
AU2010200497B2 (en) 2014-10-23
EP2107069B1 (en) 2013-01-16
IL172980A0 (en) 2006-06-11
CY1113850T1 (el) 2015-11-04
NO2024003I1 (no) 2024-01-16
KR101159559B1 (ko) 2012-06-26
CY2013027PI2 (el) 2015-11-04
BRPI0413276B8 (pt) 2021-05-25
RU2008152033A (ru) 2010-07-10
JP2007523881A (ja) 2007-08-23
NO2018003I1 (no) 2018-01-11
EP2264065A2 (en) 2010-12-22
US20140349925A1 (en) 2014-11-27
NO20061026L (no) 2006-03-02
FR13C0038I1 (fr) 2013-08-09
HUS1300033I1 (hu) 2016-08-29
KR20060132543A (ko) 2006-12-21

Similar Documents

Publication Publication Date Title
HUS1300033I1 (hu) Új inzulin származékok
IL169905A0 (en) Novel 2-pyridinecarboxamide derivatives
IL174154A0 (en) Novel glp-1 derivatives
PL2275439T3 (pl) Nowe pochodne insuliny
PL1694385T3 (pl) Zestaw do infuzji
SI1594840T1 (sl) Derivati piperidin-benzensulfonamida
GB0317665D0 (en) Qinazoline derivatives
PL1682493T3 (pl) Pochodne amidoacetonitrylu
SI1606277T1 (sl) Derivati imidazol-4-il-etinil-piridina
TWI368482B (en) New 2-pyridinylethylbenzamide derivatives
AU2003259457A8 (en) Auto-destructible syringe
IL176562A0 (en) Amidopyrazole derivative
IL175189A0 (en) N-thiazol-2-yl-benzamide derivatives
PT1706373E (pt) Derivados de amidoacetonitrilo
GB0329269D0 (en) Syringe
GB0312368D0 (en) Novel ureido- and amido-pyrazolone derivatives
GB2401043B (en) Drug
GB0319793D0 (en) Pyridinylmorpholine derivatives
EP1624073A4 (en) DRUG
TWI341309B (en) Heteroarylcarbamoylbenzene derivatives
AU2003280821A8 (en) Beauveriolide derivative
AU2003280822A8 (en) Beauveriolide derivatives
GB0319148D0 (en) Azaquinazoline derivatives
HU0300481D0 (en) Syringe
GB0318854D0 (en) Self-sterilising syringe